View in Other Languages

Regeneus Ltd

ASX:RGS ISIN:AU000000RGS6

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address significant unmet medical needs in the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain and dermatology.

       

News

Regeneus Ltd (ASX:RGS) Receives Milestone Payment from Kyocera

🕔8/28/2020 10:06:35 AM 1119

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce that is has received a payment of 100M JPY (~A$1.3M) from Kyocera Corporation (Kyocera, TYO:6971)

Read Full Article

Regeneus Ltd (ASX:RGS) To present at FNN Virtual Investor Event

🕔8/25/2020 11:39:09 AM 944

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that its CEO Leo Lee, will present at the Finance News Network (FNN) CEO Showcase virtual event on Tuesday 25 August 2020 at 12:55pm (AEST). The event is primarily attended by Australian-based retail investors and advisors.

Read Full Article

Regeneus Ltd (ASX:RGS) US Patent for Sygenus

🕔8/19/2020 9:26:38 AM 905

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the U.S Patent and Trademark Office (USPTO) has issued a notice of allowance for issuance of a new key patent for the Company's Secretome technology platform, Sygenus, in the U.S.

Read Full Article

Regeneus Ltd (ASX:RGS) and Kyocera Sign Progenza OA Deal

🕔8/11/2020 9:51:25 AM 1128

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that Kyocera Corporation (Kyocera, TYO:6971) has signed a licence agreement to develop and commercialise Progenza for Knee Osteoarthritis (Progenza OA) in Japan.

Read Full Article

Regeneus Ltd (ASX:RGS) Quarterly Report

🕔7/31/2020 4:04:34 PM 937

During the quarter, Regeneus Ltd (ASX:RGS) received notification from Kyocera Corporation (TYO:6971) that its lead stem cell platform technology Progenza for the treatment of Knee Osteoarthritis (Progenza OA) had passed Kyocera's due diligence process.

Read Full Article

Regeneus Ltd (ASX:RGS) Progenza OA Kyocera Negotiations Update

🕔7/28/2020 9:34:41 AM 870

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today provides an update on its negotiations with Kyocera Corporation (TYO:6971) for a licence agreement to develop and commercialise Progenza for Knee Osteoarthritis in Japan

Read Full Article

Regeneus Ltd (ASX:RGS) Featured in Morgans' 'Under The Microscope' Podcast series

🕔7/11/2020 9:00:15 AM 1450

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, was recently featured in the 'Under the Microscope' podcast series from Morgans.

Read Full Article

Regeneus Ltd (ASX:RGS) Director Resignation

🕔6/4/2020 10:53:55 AM 1265

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that non-executive director Dr Glen Richards has resigned to allow him to focus on his other commitments.

Read Full Article

Regeneus Ltd (ASX:RGS) Kyocera completes Progenza Due Diligence

🕔5/18/2020 8:39:52 AM 1640

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that it has received notification that Kyocera Corporation (TYO:6971) has completed its due diligence process on its lead stem cell platform technology Progenza for treatment of Knee Osteoarthritis (Progenza OA).

Read Full Article

Regeneus Ltd (ASX:RGS) Quarterly Report

🕔4/29/2020 10:35:36 AM 1632

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today released its quarterly cashflow report and review of operational activities for the period ending 31 March 2020.

Read Full Article
###

147,806 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 272) (Last 30 Days: 1302) (Since Published: 70476) 

Company Data

    Headquarters
  • 2 Paddington Street
    Paddington NSW 2021
    Australia
  • Telephone
  • +61-2-9499-8010 
  • Fax
  • +61-2-9499-8020 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.regeneus.com.au
  • E:
  • info@regeneus.com.au

Company Reports